A Bioequivalence Study Of Ethinylestradiol + Gestodene In Female And Healthy Volunteers.

This study has been completed.
Sponsor:
Information provided by:
Pfizer
ClinicalTrials.gov Identifier:
NCT01260805
First received: December 14, 2010
Last updated: February 18, 2011
Last verified: February 2011
  Purpose

A Phase I, Open Label, Randomized, Two-way Crossover, Single Dose Study to Determine the Bioequivalence of Ethinylestradiol + Gestodene - The objective of the study is to verify through a single dose study, if the two formulations of Ethinylestradiol 0,02mg + Gestodene 0,075mg sugar coated tablets are bioequivalent when administered at the same dose and under fasting conditions.


Condition Intervention Phase
Bioequivalence
Ethinylestradiol
Gestodene
Harmonet
Drug: Reference Drug
Drug: Test Drug
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Bio-equivalence Study
Intervention Model: Crossover Assignment
Masking: Open Label
Official Title: A Phase I, Open Label, Randomized, Two-Way Crossover, Single Dose Study To Determine The Bioequivalence Of Ethinylestradiol + Gestodene - Harmonet 0,02mg + 0,075mg (Laboratórios Pfizer Ltda.) In The Sugar Coated Tablets Form, Versus Femiane® 0,02mg + 0,075mg (Schering Do Brasil Química E Farmacêutica Ltda.), In The Sugar Coated Tablets Form, Under Fasted Conditions In Female And Healthy Volunteers.

Resource links provided by NLM:


Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Maxium concentration (Cmax) for ethinylestradiol/gestodene in plasma [ Time Frame: Up to 96h / Up to 144h ] [ Designated as safety issue: No ]
  • Area under the plasma/serum/blood concentration(AUC0-t) time curve from time zero to time t for ethinylestradiol/gestodene [ Time Frame: Up to 96h / Up to 144h ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Area under the curve (AUC0-inf) for ethinylestradiol/gestodene [ Time Frame: Up to 96h / Up to 144h ] [ Designated as safety issue: No ]
  • Time of maximum concentration (Tmax) for ethinylestradiol/gestodene in plasma [ Time Frame: Up to 96h / Up to 144h ] [ Designated as safety issue: No ]
  • Elimination of half-life(T1/2) for ethinylestradiol/gestodene [ Time Frame: Up to 96h / Up to 144h ] [ Designated as safety issue: No ]
  • K el for ethinylestradiol/gestodene [ Time Frame: Up to 96h / Up to 144h ] [ Designated as safety issue: No ]
  • Area under the curve from the time of dosing (AUC t/inf) extrapolated to infinity for ethinylestradiol/gestodene [ Time Frame: Up to 96h / Up to 144h ] [ Designated as safety issue: No ]

Estimated Enrollment: 32
Study Start Date: September 2010
Study Completion Date: October 2010
Primary Completion Date: October 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Reference Drug Drug: Reference Drug
Femiane® Ethinylestradiol 0,02mg + Gestodene 0,075mg sugar coated tablets single dose
Active Comparator: Test Drug Drug: Test Drug
Harmonet® Ethinylestradiol 0,02mg + Gestodene 0,075mg sugar coated tablets single dose

Detailed Description:

Bioequivalence Study

  Eligibility

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy female subjects in childbearing age, between the ages of 18 and 45 years, inclusive (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead ECG and clinical laboratory tests).
  • The BMI - Body Mass Index of the volunteers should be within the range of 18,5 to 24,9 (Dietary Guidelines for Americans) and it may vary up to 10% due to the upper limit (18,5 to 27,39) and total body weight >50kg
  • Do not be a smoker (at least 3 months);
  • Not be using hormone contraceptives for at least 28 days before the medication dosing;
  • Women with a regular menstrual cycle (menstrual cycle that occurs, in average, in each 28 days, varying from 25 to 35 days);
  • Use lubricated condoms with spermicidal or diaphragm with spermicidal (in accordance with the volunteer's preference)
  • Systolic Pressure up to 130mmHg;
  • Diastolic Pressure up to 85mmHg;
  • An informed consent document signed and dated by the subject or a legally acceptable representative. If the subject and/or legally acceptable representative cannot read, then the informed consent document may be signed by an impartial witness.
  • Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

Exclusion Criteria:

  • Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
  • The volunteer has a drug abuse history [subjects using marijuana and hashish will be excluded if they have used these drugs less than three months prior to the medical consult and for drugs such as cocaine, phencyclidine (PCP), crack and heroin, volunteers will be excluded that have used these drugs less than 1 year prior to the medical consult.
  • A positive exam for drugs in urine (Methamphetamine, Opiate, Morphine, Marijuana, Cannabis, Amphetamine, Coccaine, Benzoylecgogine, Benzodiazepine) or a positive test for alcohol before the internment in periods 1 and 2.
  • History of regular alcohol consumption exceeding 7 drinks/week (1 drink = 150 mL of wine or 360 mL of beer or 45 mL of hard liquor) within 6 months of screening.
  • The volunteer is a smoker or having stopped smoking less than 3 months
  • The volunteer has participated of any experimental trial or has ingested any experimental drug within the 6 months that precede the beginning of the study (ANVISA: Resolution RDC nº34, from June 3rd 2008).
  • 12-lead ECG demonstrating QTc >450 msec at screening. If QTc exceeds 450 msec, the ECG should be repeated two more times and the average of the three QTc values should be used to determine the subject's eligibility.
  • Pregnant or nursing females; females of childbearing potential who are unwilling or unable to use an acceptable method of non-hormonal contraception as outlined in this protocol from at least 14 days prior to the first dose of study medication.
  • Use of prescription or nonprescription drugs and dietary supplements within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study medication. Herbal medicine, herbal supplements must be discontinued 28 days prior to the first dose of study medication. Limited use of non-prescription medications that are not believed to affect subject safety or the overall results of the study may be permitted on a case-by-case basis following approval by the sponsor.
  • Hormonal methods of contraception (including oral and transdermal contraceptives, injectable progesterone, progestin subdermal implants, progesterone-releasing IUDs, postcoital contraceptive methods) and hormone replacement therapy must be discontinued 28 days prior to the first dose of study medication.
  • Implant (ex. Norplant®) or a progesterone depot injection (ex. Depo-Provera®) or the use of any dispositive for the long term treatment with progesterone or estrogens (ex. Estring®) up to 6 months before the administration of the medication in study;
  • A depot injection or an implant of any active ingredient up to 3 months before the administration of the medication in study;
  • Have used an injection contraceptive of Medroxyprogesterone Acetate one year before the beginning of the study;
  • Have had sexual intercourse without a contraceptive method (preservative, IUD, diaphragm with spermicidal) within the last 14 days.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01260805

Locations
Brazil
Pfizer Investigational Site
Aparecida de Goiania, GO, Brazil, 74935-530
Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
No publications provided

Responsible Party: Director, Clinical Trial Disclosure Group, Pfizer, Inc.
ClinicalTrials.gov Identifier: NCT01260805     History of Changes
Other Study ID Numbers: B3341001, ICF PBIO 071/10 APH 100214
Study First Received: December 14, 2010
Last Updated: February 18, 2011
Health Authority: Brazil: ANVISA - National Health Surveillance Agency

Keywords provided by Pfizer:
bioequivalence
study
ethinylestradiol
gestodene

Additional relevant MeSH terms:
Ethinyl Estradiol
Gestodene
Femovan
Estrogens
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Pharmacologic Actions
Contraceptives, Oral, Combined
Contraceptives, Oral
Contraceptive Agents, Female
Contraceptive Agents
Reproductive Control Agents
Therapeutic Uses
Contraceptives, Oral, Synthetic
Progestins

ClinicalTrials.gov processed this record on September 11, 2014